BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol. 2001;8:411-416. [PMID: 11604584 DOI: 10.1097/00062752-200111000-00016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Lv W, Qu H, Wu M, Fan Z, Huang F, Xu N, Xuan L, Lin R, Zhao K, Sun J, Lai Y, Xu Y, Liu Q. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience. Cancer Med 2019;8:6549-58. [PMID: 31502764 DOI: 10.1002/cam4.2539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
2 Dhingra S, Wiener JJ, Jackson H. Management of cold agglutinin immune hemolytic anemia in pregnancy. Obstet Gynecol 2007;110:485-6. [PMID: 17666637 DOI: 10.1097/01.AOG.0000259908.18243.f0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-andersen T, Plesner T, Rønnov-jessen D, Vestergaard H, Klausen TW, Schöllkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013;163:393-9. [DOI: 10.1111/bjh.12541] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
4 Vassiliadis T, Garipidou V, Perifanis V, Tziomalos K, Giouleme O, Patsiaoura K, Avramidis M, Nikolaidis N, Vakalopoulou S, Tsitouridis I, Antoniadis A, Semertzidis P, Kioumi A, Premetis E, Eugenidis N. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006;12:818-21. [PMID: 16521204 DOI: 10.3748/wjg.v12.i5.818] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Laribi K, Bolle D, Ghnaya H, Sandu A, Besançon A, Denizon N, Truong C, Pineau-Vincent F, de Materre AB. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Ann Hematol 2016;95:765-9. [PMID: 26858026 DOI: 10.1007/s00277-016-2605-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hendrick AM. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology 2003;8:53-6. [PMID: 12623428 DOI: 10.1080/1024533021000059474] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
7 Michel M. Caractéristiques des anémies hémolytiques auto-immunes à anticorps « chauds » et du syndrome d’Evans de l’adulte. La Presse Médicale 2008;37:1309-18. [DOI: 10.1016/j.lpm.2008.01.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
8 Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220-229. [PMID: 21570637 DOI: 10.1016/j.ejim.2010.12.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
9 Rodella E, Pacquola E, Bianchini E, Ramazzina E, Paolini R. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. Blood Coagul Fibrinolysis 2008;19:315-8. [PMID: 18469554 DOI: 10.1097/MBC.0b013e3282f9ae12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG. Levofloxacin-induced autoimmune hemolytic anemia. Ann Pharmacother 2003;37:1010-3. [PMID: 12841809 DOI: 10.1345/aph.1C525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Petz LD, Garratty G. Management of Autoimmune Hemolytic Anemias. Immune Hemolytic Anemias. Elsevier; 2004. pp. 401-58. [DOI: 10.1016/b978-0-443-08559-8.50015-7] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
12 Sukhal S, Gupta S. Drug-induced immune haemolytic anaemia caused by levofloxacin. Singapore Med J 2014;55:e136-8. [PMID: 25189315 DOI: 10.11622/smedj.2014111] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lecouffe-Desprets M, Néel A, Graveleau J, Leux C, Perrin F, Visomblain B, Artifoni M, Masseau A, Connault J, Pottier P, Agard C, Hamidou M. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study. Autoimmun Rev 2015;14:1023-8. [PMID: 26162301 DOI: 10.1016/j.autrev.2015.07.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
14 Liu B, Gu W. Immunotherapy treatments of warm autoimmune hemolytic anemia. Clin Dev Immunol 2013;2013:561852. [PMID: 24106518 DOI: 10.1155/2013/561852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. Journal of Internal Medicine 2010;267:260-77. [DOI: 10.1111/j.1365-2796.2009.02207.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
16 Sève P, Philippe P, Dufour JF, Broussolle C, Michel M. Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol 2008;1:189-204. [PMID: 21082924 DOI: 10.1586/17474086.1.2.189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
17 Sudulagunta SR, Kumbhat M, Sodalagunta MB, Settikere Nataraju A, Bangalore Raja SK, Thejaswi KC, Deepak R, Mohammed AH, Sunny SP, Visweswar A, Suvarna M, Nanjappa R. Warm Autoimmune Hemolytic Anemia: Clinical Profile and Management. J Hematol 2017;6:12-20. [PMID: 32300386 DOI: 10.14740/jh303w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 De Keyzer K, Peeters P, Verhelst C, Dendooven A, Vonck A, Vanholder R. Autoimmune haemolytic anaemia associated with a thymoma: case report and review of the literature. Acta Clin Belg 2009;64:447-51. [PMID: 19999396 DOI: 10.1179/acb.2009.075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
19 Sève P, Bourdillon L, Sarrot-Reynauld F, Ruivard M, Jaussaud R, Bouhour D, Bonotte B, Gardembas M, Poindron V, Thiercelin MF, Broussolle C, Oksenhendler E; DEF-I Study Group. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore) 2008;87:177-84. [PMID: 18520327 DOI: 10.1097/MD.0b013e31817a90ba] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
20 Michel M. [Warm autoimmune hemolytic anemias and Evans syndrome in adults]. Rev Med Interne 2008;29:105-14. [PMID: 17980462 DOI: 10.1016/j.revmed.2007.08.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
21 Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149-69. [DOI: 10.1111/j.1365-2141.2008.07054.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 109] [Article Influence: 11.7] [Reference Citation Analysis]
22 Jordan SD, Alexander E. Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia. J Pharm Pract 2013;26:257-60. [PMID: 22869910 DOI: 10.1177/0897190012451928] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhang Y, Qui Y, Zhu J, Gao D. Pulmonary hypertension associated with autoimmune hemolytic anemia: a case report. Int J Cardiol. 2007;115:e1-e2. [PMID: 16889843 DOI: 10.1016/j.ijcard.2006.05.053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
24 Lacaille F, Moes N, Hugot J, Cezard J, Goulet O, Ruemmele FM. Severe Dysimmune Cytopenia in Children Treated with Tacrolimus After Organ Transplantation: Dysimmune Cytopenia After Transplantation. American Journal of Transplantation 2006;6:1072-6. [DOI: 10.1111/j.1600-6143.2006.01304.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
25 Botija G, Ybarra M, Ramos E, Molina M, Sarría J, Martínez-ojinaga E, Andrés AM, López-santamaría M, Prieto G. Autoimmune cytopaenia after paediatric intestinal transplantation: a case series: Autoimmune cytopaenia after paediatric intestinal transplantation: a case series. Transplant International 2010;23:1033-7. [DOI: 10.1111/j.1432-2277.2010.01091.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
26 Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apheresis 2007;22:106-75. [DOI: 10.1002/jca.20129] [Cited by in Crossref: 178] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
27 Lv W, Fan Z, Huang F, Xu N, Xuan L, GuopanYu, Jiang Q, Zhou H, Lin R, Zhang X, Sun J, Liu Q. Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell Transplant compared with matched sibling and unrelated donor. Oncotarget 2017;8:26505-14. [PMID: 28460445 DOI: 10.18632/oncotarget.15710] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 366] [Cited by in F6Publishing: 275] [Article Influence: 33.3] [Reference Citation Analysis]
29 Gao QY, Liu CX, Li Y, Peng GX, Li JP, Li Y, Ye L, Fan HH, Song L, Zhang L, Jing LP, Zhou K, Zhao X, Yang WR, Wu ZJ, Yang Y, Xiong YZ, Zhang FK. [A monocentric retrospective study of low-dose rituximab in the treatment of 12 cases refractory or relapsed idiopathic autoimmune hemolytic anemia patients]. Zhonghua Xue Ye Xue Za Zhi 2017;38:1075-7. [PMID: 29365406 DOI: 10.3760/cma.j.issn.0253-2727.2017.12.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 King KE, Ness PM. Treatment of Autoimmune Hemolytic Anemia. Seminars in Hematology 2005;42:131-6. [DOI: 10.1053/j.seminhematol.2005.04.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
31 Mcleod BC. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias: . Current Opinion in Hematology 2007;14:647-54. [DOI: 10.1097/moh.0b013e3282c8ca66] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
32 Bussone G, Hachulla E, Sibilia J, Michel M, Godeau B, Guillevin L, Mouthon L. Rituximab et traitement des maladies auto-immunes et inflammatoires systémiques. La Presse Médicale 2009;38:808-23. [DOI: 10.1016/j.lpm.2009.02.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Trivedi DH, Bussel JB. 21. Immunohematologic disorders. Journal of Allergy and Clinical Immunology 2003;111:S669-76. [DOI: 10.1067/mai.2003.157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Teachey DT, Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 2013;60:1489-511. [PMID: 24237984 DOI: 10.1016/j.pcl.2013.08.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
35 Ruivard M, Tournilhac O, Montel S, Fouilhoux A, Quainon F, Lénat A, Travade P, Philippe P. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. J Clin Apheresis 2006;21:202-6. [DOI: 10.1002/jca.20096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
36 Campbell R, Marik PE. Severe autoimmune hemolytic anemia treated by paralysis, induced hypothermia, and splenic embolization. Chest 2005;127:678-81. [PMID: 15706015 DOI: 10.1378/chest.127.2.678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
37 Bratkovic K, Fahy C. Anesthesia for off-pump coronary artery surgery in a patient with cold agglutinin disease. J Cardiothorac Vasc Anesth 2008;22:449-52. [PMID: 18503940 DOI: 10.1053/j.jvca.2007.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Aglieco F, Manickaratnam S, Bona R, Kaplan AA. A Case Report of Refractory Warm Autoimmune Hemolytic Anemia Treated With Plasmapheresis and Rituximab. Therapher Dial 2008;12:185-9. [DOI: 10.1111/j.1744-9987.2008.00568.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, Díaz-Mediavilla J, Bustelos R, Fernández-Aceñero MJ, Cabrera JR; Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010;89:1073-80. [PMID: 20526716 DOI: 10.1007/s00277-010-0997-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
40 Jaime-pérez JC, Rodríguez-martínez M, Gómez-de-león A, Tarín-arzaga L, Gómez-almaguer D. Current Approaches for the Treatment of Autoimmune Hemolytic Anemia. Arch Immunol Ther Exp 2013;61:385-95. [DOI: 10.1007/s00005-013-0232-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
41 Bussone G, Ribeiro E, Dechartres A, Viallard J, Bonnotte B, Fain O, Godeau B, Michel M. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases. Am J Hematol 2009;84:153-7. [DOI: 10.1002/ajh.21341] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
42 Powell DJ, Achebe MO. Anemia for the Primary Care Physician. Prim Care 2016;43:527-42. [PMID: 27866575 DOI: 10.1016/j.pop.2016.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
43 Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. Blood Transfus 2009;7:216-34. [PMID: 19657486 DOI: 10.2450/2009.0094-09] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
44 Ramanathan S, Koutts J, Hertzberg M. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 2005;78:123-6. [DOI: 10.1002/ajh.20220] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]